Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. - Wikidata - awgldk - TriplyDB

Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.

Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.

http://www.wikidata.org/entity/Q30465168

about

Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials Therapeutic potential of microRNA: a new target to treat intrahepatic portal hypertension?Pathophysiology of portal hypertension Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice Evolving therapies for liver fibrosis.Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis Preventive effect of halofuginone on concanavalin A-induced liver fibrosis.Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition The chinese herbal decoction danggui buxue tang inhibits angiogenesis in a rat model of liver fibrosis.Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells.Vascular endothelial growth factor promotes fibrosis resolution and repair in mice.Future treatments of cirrhosis.Antifibrotic therapies in the liver.Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights.Effect of halofuginone on the inhibition of proliferation and invasion of hepatocellular carcinoma HepG2 cell line.Portal myofibroblasts connect angiogenesis and fibrosis in liver.New approaches for fibrosis regression in alcoholic cirrhosis.Endostar, a novel human recombinant endostatin, attenuates liver fibrosis in CCl4-induced mice.Angiogenesis and Fibrogenesis in Chronic Liver Diseases.Molecular pathophysiology of portal hypertension.Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.Distinguishing between Hepatic Inflammation and Fibrosis with MR Elastography.Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib.Vatalanib, a tyrosine kinase inhibitor, decreases hepatic fibrosis and sinusoidal capillarization in CCl4-induced fibrotic mice.Levistilide A inhibits angiogenesis in liver fibrosis via vascular endothelial growth factor signaling pathway.Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma.The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis.Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives Curcumin analog, GO-Y078, overcomes resistance to tumor angiogenesis inhibitors

P2860

Q26771518-9F9BC2A3-52A3-46C8-BDB8-20E954799236 Q26772800-770AB19F-0A4A-4A6D-B1C2-EB4CA7ADDAE4 Q26829662-D2E26999-D3B7-4694-983F-2AED4C0B2003 Q27026406-BD803234-6F01-4DE8-BA89-67F27128B08B Q28068710-2ACB6E47-3445-4AFA-B4A3-0A13F1229D71 Q28085644-2A2470DB-3ADA-4F12-93AA-5F9ECFAD24B3 Q30511815-E1305D85-7F78-4A1E-9C50-CDA283018233 Q30539166-0A50844C-606A-4A99-B026-FE5BACA272B9 Q34902424-D4BB48A5-321A-4FA5-B683-2C9A044F2B25 Q35072681-8E823701-6147-4BC5-9875-7EB341FD4E39 Q35136411-A5193FC2-4309-4B87-AF0D-867B743D581C Q35560583-DF87898E-E5B6-4894-BDCE-D78510727DA8 Q35740334-9A0F3FCA-C1B1-4C4C-BEA8-6C7817FC48AA Q36180467-40F0749F-6B60-4442-82D2-F175167882C5 Q37262768-0D10F631-94BC-4D97-A7A5-D8DA9630C291 Q37678954-16E3F636-5876-4ABB-AE07-D486F8D754AF Q37726957-FBB02372-C677-48A0-8B42-06D14EAE8A7D Q38218607-3B1FFFA5-C438-420B-93ED-99A9BEF5BC0A Q38480164-C8FC010B-50EB-4D8E-8116-6D502BE4C5D7 Q38759447-3DB670E6-2850-46BE-8C49-E8E059AF9E86 Q38793565-6DDF778F-6B35-46CB-B033-061A256A9533 Q38870907-0B033355-327C-4423-947C-5586BE0A432F Q38909134-51CE1F82-984E-484F-8E11-55AC6578701D Q38990632-4B04C12D-CBA3-4E03-901D-19FB91C6CBC2 Q39140170-3BE1EAF4-576B-488E-9F36-21EFCF0DC59E Q39148718-B098441B-CD38-4E15-94F1-9BCCB6EC2D48 Q39291844-261C16DF-2BA4-4F99-B309-DE23139F2492 Q41139413-FE3A7169-04FD-47AE-A069-9D9B4F01A9D2 Q41494907-28DB26CF-9AB7-43D4-867D-1323D90D8354 Q42273298-742B75C8-1FAE-4280-B9B3-EECE5E76F73D Q43104909-75ED05E9-3987-4F37-9AE0-2F7333C243E9 Q48635527-A4A15D78-3639-49DB-A6B1-341268856A5E Q51740036-90DE24D5-0438-4393-8166-F18396823176 Q53381128-33637F51-D987-4798-88A7-42AD1B421502 Q57146377-9272F42E-8C93-4E73-9818-455842598B13 Q58760398-38AFF6C9-A25C-4FEA-8195-D37870BAE335 Q58772394-BBE312B8-7A34-4309-BE6F-BEE6EDBD4360

P2860

Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.

http://www.wikidata.org/entity/Q30465168

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Complementary vascular and mat ...... f sorafenib in liver fibrosis.

@ast

Complementary vascular and mat ...... f sorafenib in liver fibrosis.

@en

type

label

Complementary vascular and mat ...... f sorafenib in liver fibrosis.

@ast

Complementary vascular and mat ...... f sorafenib in liver fibrosis.

@en

prefLabel

Complementary vascular and mat ...... f sorafenib in liver fibrosis.

@ast

Complementary vascular and mat ...... f sorafenib in liver fibrosis.

@en

P1433

Q30465168-86CF48E7-0652-4F6F-9AAD-EEA1FD0D3CCF

P1476

Q30465168-160106F6-C6E8-404C-82F2-1EF70C19D630

P2093

Q30465168-0A0340A9-E623-4DCF-AD7B-97BB652F0CBF

Q30465168-0AEEA134-2C8A-40DE-B45D-53BD06BEF451

Q30465168-0BC5E724-9025-4D4F-B9AC-4EB03439DA4D

Q30465168-54516258-E09D-4231-8C99-9FC0536C538E

Q30465168-6B10ED98-F208-47E9-976D-D009AA40F571

Q30465168-7A1F4DBB-A7EB-4A22-BDD4-9695BD084773

Q30465168-82905B5A-B470-4E44-A75C-2974D5D1653A

Q30465168-A2EF0542-59AA-4E2B-A87A-181E66737E2E

Q30465168-B5575B65-1402-4033-B233-00C636820FBD

Q30465168-BC528823-9AF4-434D-976B-CE41954C11A3

P2860

Q30465168-00043D64-14B9-4897-806F-5CFDAC19344E

Q30465168-0BD965D5-21CF-445E-AC21-9C16CF2452B1

Q30465168-16F58B45-6FE3-4810-B936-2DC7662577E5

Q30465168-173EAFE9-2C10-4732-B2DD-CCF0E24F5008

Q30465168-24606ED4-6F40-4963-9325-4D0B60C410A7

Q30465168-27A8BE3A-652A-463D-A52C-8695CC3392FF

Q30465168-305E912E-2276-4300-A04E-F16C4ED8842C

Q30465168-3303114D-4DE0-4565-969F-79BD8A04B4DB

Q30465168-388E9CC1-CDC2-4721-AEB8-8FEFF220F230

Q30465168-4F4247EA-DF6D-45CF-B61A-85B149AB8910

P304

Q30465168-C7B50CEA-AD59-4585-ABB8-9A67B429C160

P31

Q30465168-82CA5C6F-CC2A-4D71-BD86-7516C695C3F1

P356

Q30465168-79D41999-799B-46EB-909C-29D585F63AAD

P407

Q30465168-2C97A895-AB58-48D2-8635-A16FE22328B3

P433

Q30465168-A1668467-7E9A-46C8-BAC2-5DB5D418E216

P478

Q30465168-932BB3D0-EA3D-4E55-8293-1F5621EE2963

P577

Q30465168-6B3BAB3E-3AF2-4EA3-92DC-E880A3FE9724

P5875

Q30465168-E25916C4-4FF3-47EE-B98D-05B2E725FB88

P698

Q30465168-1F774513-6392-411B-A585-B44EFF5CAA79

P932

Q30465168-8D76AA22-3B01-4D68-8236-BE89FAABFBC9

P356

P1433

P1476

Complementary vascular and mat ...... f sorafenib in liver fibrosis.

@en

P2093

Andrew Vercnocke

http://www.w3.org/2001/XMLSchema#string

Boris Blechacz

http://www.w3.org/2001/XMLSchema#string

Chittaranjan Routray

http://www.w3.org/2001/XMLSchema#string

Dominique Thabut

http://www.w3.org/2001/XMLSchema#string

Erik Ritman

http://www.w3.org/2001/XMLSchema#string

Gwen Lomberk

http://www.w3.org/2001/XMLSchema#string

Kevin Glaser

http://www.w3.org/2001/XMLSchema#string

Leena Patel

http://www.w3.org/2001/XMLSchema#string

Raul Urrutia

http://www.w3.org/2001/XMLSchema#string

Richard Ehman

http://www.w3.org/2001/XMLSchema#string

P2860

Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis

Sorafenib in advanced hepatocellular carcinoma

Magnetic resonance elastography by direct visualization of propagating acoustic strain waves

Molecular regulation of vessel maturation

Endothelial/pericyte interactions

Zonula occludens-1 function in the assembly of tight junctions in Madin-Darby canine kidney epithelial cells.

Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function.

Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury.

The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease

Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2

P304

573-585

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.24427

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51122142

http://www.w3.org/2001/XMLSchema#string

P698

21567441

http://www.w3.org/2001/XMLSchema#string

P932

3145033

http://www.w3.org/2001/XMLSchema#string